The PROTEUS Trial: Perioperative Apalutamide Shows Positive Results for Prostate Cancer

The PROTEUS phase 3 trial, published in the New England Journal of Medicine, shows that adding perioperative apalutamide to androgen-deprivation therapy significantly improves outcomes for men with high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy. The international trial randomized 2,109 patients to six cycles of ADT plus apalutamide (240 mg daily) or ADT […]